GlobalData on MSN8d
EC approves CSL’s Andembry to stop hereditary angioedema attacks
CSL has received approval from the European Commission (EC) for Andembry (garadacimab) to prevent recurrent attacks of ...
Astria Therapeutics: A High-Conviction Bet On HAE
Astria advances innovative therapies for hereditary angioedema and atopic dermatitis. Strong cash position supports pivotal ...
KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that six abstracts have been accepted for presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy ...
Nasdaq2d
New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control
“In new analyses from our OASISplus prospective switch cohort, donidalorsen continued to demonstrate the ability to reduce the HAE attack ... acute attacks of hereditary angioedema (HAE).
Nasdaq12d
BioCryst Pharmaceuticals to Present New Clinical Findings on ORLADEYO® for Hereditary Angioedema at AAAAI/WAO Joint Congress 2025
(berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. Limitations of use ...
Medscape1d
Conference MDAngle: AAAAI/WAO 2025
Dr Ruchi Gupta provides AAAAI/WAO 2025 highlights, including anticipated presentations, quick takeaways, and insights into ...
Morningstar9d
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
ANDEMBRY®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients ... in the management of hereditary angioedema, offering people living with this ...
GlobalData on MSN1d
Japan’s MHLW approves CSL Behring’s Andembry to stop HAE attacks
CSL Behring KK has gained approval from Japan's Ministry of Health, Labour and Welfare (MHLW) to manufacture and market ...
PMLiVE8d
EC approves CSL’s Andembry to prevent hereditary angioedema attacks
The European Commission (EC) has approved CSL’s Andembry (garadacimab) to prevent attacks of hereditary angioedema (HAE) in ...
Business Wire1d
KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
On-demand Treatment Of Hereditary Angioedema Attacks With Sebetralstat In Adolescents: Pooled Analysis From KONFIDENT And KONFIDENT-S (#552): Danny Cohn, Aharon Kessell, Tamar Kinaciyan ...
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that the European Commission (EC) has approved ...